Today's Healthcare Pulse
Pharma Shifts Ad Spend to Spot TV Amid Heightened FDA Scrutiny
Pharmaceutical advertisers are redirecting dollars toward spot television placements as the FDA intensifies its oversight of drug marketing. The trend reflects a strategic move to capture audiences with shorter, targeted ads while navigating tighter regulatory expectations.
Also developing:
By the numbers: Apogee Therapeutics secures $1.3B royalty financing
Brazil Fights Back Tobacco Harms
Brazil, long hailed for its robust tobacco‑control framework, is now confronting a new threat: vaping. Cities such as Rio de Janeiro have launched hundreds of inspections and enacted stricter ordinances that ban e‑cigarette use in public spaces. Complementary public‑awareness campaigns aim to prevent nicotine addiction from being renormalized among youth. The coordinated effort demonstrates how government action can extend past successes in traditional tobacco control to emerging products.
Will the Medicare ACCESS Model Spark the Next Health Tech Gold Rush?
The Health Affairs podcast introduces Medicare’s new ACCESS model, launching in July 2026. ACCESS—Advancing Chronic Care with Effective Scalable Solutions—will allow Medicare beneficiaries and their physicians to claim reimbursement for digital health products such as mobile disease‑management apps and wearable...
Healthcare AI Success Starts With Defining the Right Problem
Healthcare leaders stress that AI projects must begin with a clear problem definition rather than jumping to solutions. The speaker describes a strict innovation framework that requires teams to articulate the demand, objectives, and expected outcomes before any technology is...
Healthcare at Home Is Closer Than You Think | Flourish Rerelease with Asim Malik
The episode spotlights the rapid rise of hospital‑at‑home and ER‑at‑home models, explaining how they shift acute care from brick‑and‑mortar facilities into patients’ residences. Host Sarah Richardson talks with Asim Malik, who recently transitioned to leading in‑home acute‑care initiatives, to unpack...
Why Japan for Drug Development Vol.2 Taking the Next Steps with Your Drug in Japan
The webinar, co‑hosted by NIK Biotechnology and sponsored by Nexera, focused on the latest PMDA initiatives that make Japan an increasingly attractive market for drug developers. Speakers highlighted Japan’s position as the world’s third‑largest pharmaceutical market, the transparency of PMDA’s...
Replimune Is Resubmitting Its Twice-Rejected Melanoma Drug After FDA Leadership Exodus
Replimune Group announced it will resubmit the biologics license application for its melanoma therapy RP1 (vusolimogene oderparevec) within days, after reaching a new agreement with the FDA. The agency’s prior two rejections stemmed from the trial’s lack of a control group,...
$3 Million Australian Digital Program Launched to Prevent Dementia Before Symptoms Appear
The Australian Government’s Medical Research Future Fund has granted $3 million to launch the Maintain Your Brain Plus (MYB+) digital program, targeting 5,000 adults aged 45‑79 in regional and rural communities. Built on the world’s largest online dementia‑prevention trial, the initiative...
Pharmacy First Prescribing Expanded to Ease GP Pressure
The UK government has unveiled a £340 million (≈ $430 million) programme to broaden the range of medicines community pharmacists in England can prescribe, adding five new therapeutic categories to the existing Pharmacy First list. The move, part of the 2024‑2025 Pharmacy First...
Junshi Biosciences Hits Primary Endpoints in Phase III NEOTORCH Study, Plans sNDA for Toripalimab
Junshi Biosciences announced that its NEOTORCH Phase III trial met its primary event‑free survival and major pathological response endpoints in 501 patients with resectable stage II‑III non‑small cell lung cancer. The company will file a supplemental new drug application to...
FDA Expands TREMFYA Label to Cover Psoriatic Arthritis Joint Damage
Johnson & Johnson’s TREMFYA (guselkumab) received FDA approval for a label expansion that now includes inhibition of structural joint damage in adults with active psoriatic arthritis. The decision follows positive results from the Phase 3b APEX trial, positioning TREMFYA as the...
Targeted Therapy Shows Superior Results Over Chemotherapy in Treating Difficult Lung Cancer, ASCO Reports
At the American Society of Clinical Oncology (ASCO) meeting, researchers presented data showing a novel targeted therapy outperformed standard chemotherapy in patients with advanced non‑small cell lung cancer (NSCLC) that are difficult to treat. The trial reported a median progression‑free...
Insilico and Human Longevity Launch Multimillion‑dollar AI Eye‑scan to Flag Disease Years Early
Insilico Medicine and Human Longevity announced a multimillion‑dollar partnership to build an AI‑driven eye‑scan platform that could identify cancer, heart disease and neurodegeneration long before clinical symptoms. The collaboration taps Insilico’s generative‑AI expertise and Human Longevity’s decade‑long patient data library,...
WHO Prioritizes Regeneron's Maftivimab for Bundibugyo Ebola Trials Amid Growing Outbreak
Regeneron Pharmaceuticals' maftivimab antibody has been recommended by the WHO Therapeutics Advisory Group for prioritized evaluation in clinical trials targeting the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo and Uganda, where 906 suspected cases and 223 deaths...
Norovirus Surge Hits U.S. Hikers and Sparks Nationwide Wastewater Alerts
A wave of norovirus cases is sweeping the United States, with CDC wastewater monitoring flagging high viral loads and dozens of hikers on the Pacific Crest Trail falling ill. Health officials warn the GII.17 strain now dominates, raising concerns about...
MIT Nanotech Catheter Spots Bladder‑cancer Biomarker 50,000× More Sensitively
MIT engineers have created a catheter lined with carbon‑nanotube sensors that can detect the bladder‑cancer biomarker NMP‑22 up to 50,000 times more sensitively than conventional urinalysis. The breakthrough, detailed in a Nature Nanotechnology paper, could enable clinicians to locate tumors...
CVS Caremark Restores Zepbound and Adds Lilly's Foundayo, Expanding Coverage to 30 Million Americans
CVS Caremark announced it will reinstate coverage of Eli Lilly’s injection Zepbound on Oct. 1 and add the newly approved oral pill Foundayo on June 1, affecting roughly 25‑30 million commercial lives. The reversal follows a 2023 formulary drop that sparked patient backlash and...
Pfizer Inks $10.5 B Oncology Partnership with China’s Innovent Biologics
Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5 billion to co‑develop 12 early‑stage oncology medicines. The deal includes a $650 million upfront cash payment, milestone payouts of up to $9.85 billion and double‑digit royalties, expanding...
Regulatory and Scientific Frontiers in Drug Repurposing: Accelerating Therapeutic Innovations for Unmet Medical Needs + Examples of Repurposed Drugs
On May 11, 2026 the FDA unveiled a formal drug‑repurposing program aimed at accelerating clinical trials for approved compounds targeting chronic, rare and underserved conditions. The initiative builds on prior legislation such as the Best Pharmaceuticals for Children Act and...
Pancreatic Cancer Halted by Virus Injection in Three Patients
In a U.S. Phase 1 safety trial, an engineered oncolytic virus halted tumor growth and prevented spread in three pancreatic cancer patients. Researchers administered only one‑tenth of the intended therapeutic dose, yet observed clear disease control. Lead developer Masato Yamamoto highlighted...
Where Medical Expertise Meets Advanced Skin Care: Manila Doctors Hospital Now Offers Skin and Laser Services
Manila Doctors Hospital (MDH) has opened a hospital‑based Skin and Laser Center within its Aesthetics Center, delivering medical‑grade dermatology and laser procedures under clinical supervision. Led by chief dermatologist Dr. Cindy Jao Tan and a team of board‑certified specialists, the...